Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 26:2021:5591137.
doi: 10.1155/2021/5591137. eCollection 2021.

Systematic Evaluation of Clinical Efficacy and Platelet Function of Sofren Injection in the Treatment of Angina Pectoris

Genhao Fan  1 , Menglin Liu  1 , Zuoying Xing  2 , Zhaoqi Chen  3 , Mingjun Zhu  2 , Yongxia Wang  2
Affiliations
Review

Systematic Evaluation of Clinical Efficacy and Platelet Function of Sofren Injection in the Treatment of Angina Pectoris

Genhao Fan et al. Evid Based Complement Alternat Med. .

Abstract

To systematically evaluate the efficacy and safety of sofren injection combined with conventional Western medicine in the treatment of angina pectoris. Randomized controlled trials (RCTs) on the treatment of angina pectoris with sofren injection combined with Western medicine were collected by searching PubMed, the Cochrane Library, Embase, Web of Science, CNKI, Wanfang Database, Weipu Database, and China Biomedical Literature Service System (CBM) by computer with the retrieval time from establishment of database to August 2020. After literature screening according to the predetermined inclusion and exclusion criteria, data of eligible studies were extracted, and then, a meta-analysis was conducted with the RevMan 5.3 software. The results of meta-analysis showed that the combination of sofren injection and Western medicine improved the platelet aggregation rate of patients (MD = -5.53, 95% CI (-6.42, -4.64), P < 0.00001), PAI-1 (SMD = -2.29, 95% CI (-2.57, -2.01), P < 0.00001), TXB2 (MD = -11.91, 95% CI (-14.50, -9.32), P < 0.00001), duration of angina attack (MD = -2.01, 95% CI (-3.14, -0.87), P=0.0005), ECG symptoms (RR = 1.29, 95% CI (1.20, 1.37), P < 0.00001), whole blood viscosity (MD = -1.07, 95% CI (-1.66, -0.48), P=0.0004), plasma viscosity (MD = -0.27, 95% CI (-0.35, -0.20), P < 0.00001), fibrinogen (MD = -0.67, 95% CI (-0.84, -0.50), P < 0.00001), whole blood high shear viscosity (MD = -1.04, 95% CI (-1.30, -0.79), P < 0.00001), whole blood low shear viscosity (MD = -2.03, 95% CI (-2.53, -1.53), P < 0.00001), CRP (MD = -1.96, 95% CI (-3.01, -0.91), P=0.0003), IL-6 (MD = -2.79, 95% CI (-4.02, -1.55), P < 0.00001), and TNF-α (MD = -17.34, 95% CI (-25.86, -8.81), P < 0.00001) and better than the Western medicine group, and there was no statistical significance in the incidence of adverse reactions between the two groups (P=0.48). The clinical application of sofren injection combined with conventional Western medicine in the treatment of angina pectoris is clear and safe, so it is recommended for clinical application.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
The document selection process and results.
Figure 2
Figure 2
Bias risk assessment table.
Figure 3
Figure 3
Meta-analysis of platelet aggregation rate in blood.
Figure 4
Figure 4
Plasma plasminogen activator inhibitor 1 meta-analysis.
Figure 5
Figure 5
Meta-analysis of thromboxin B2.
Figure 6
Figure 6
Meta-analysis of the duration of angina attack.
Figure 7
Figure 7
Meta-analysis of symptom improvement of electrocardiogram.
Figure 8
Figure 8
Meta-analysis of whole blood viscosity.
Figure 9
Figure 9
Meta-analysis of plasma viscosity.
Figure 10
Figure 10
Meta-analysis of fibrinogen.
Figure 11
Figure 11
Meta-analysis of whole blood high shear viscosity.
Figure 12
Figure 12
Meta-analysis of whole blood low shear viscosity.
Figure 13
Figure 13
Meta-analysis of C-reactive protein.
Figure 14
Figure 14
Meta-analysis of interleukin-6.
Figure 15
Figure 15
Meta-analysis of TNF-α.
Figure 16
Figure 16
Meta-analysis of adverse reactions.
Figure 17
Figure 17
Infundibular diagram of therapeutic effect of electrocardiogram.
See this image and copyright information in PMC

References

    1. Balla C., Pavasini R., Ferrari R. Treatment of angina: where are we? Cardiology. 2018;140(1):52–67. doi: 10.1159/000487936. - DOI - PubMed
    1. Maddox T. M., Reid K. J., Spertus J. A., et al. Angina at 1 Year after myocardial Infarction Prevalence and associated findings. Archives of Internal Medicine. 2008;168(12):1310–1316. doi: 10.1001/archinte.168.12.1310. - DOI - PubMed
    1. Gilles M., Udo S., Stephan A., et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34(38):2949–3003. - PubMed
    1. Zhang J., Yang B. S., Wang Y. J. Research progress on treatment of coronary heart disease by sofren injection. Clinical Journal of Medical Officers. 2016;44(05):545–546.
    1. Anderson J. L. ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable Angina/non–ST-elevation myocardial infarction. Journal of the American College of Cardiology. 2012;61(23):179–347. - PubMed

LinkOut - more resources